Every year, the far south coast community is ready and waiting as the Sydney to Hobart Yacht Race fleet comes streaming ...

Master Lock Comanche has claimed a famous victory in the 2025 Sydney to Hobart Yacht Race. It took two days and five hours ...

The Sydney to Hobart Yacht Race, one of the most prestigious events in the sailing calendar, has seen significant challenges as more than a quarter of its fleet has retired. As the leading yachts ...

Crews have been battling challenging conditions, damage and sea sickness as the leading yachts are expected to arrive in ...

Shares in Minerva Neurosciences have lost more than half their value after the FDA rejected its marketing application for roluperidone as a treatment for the negative symptoms of schizophrenia. In a ...

From Basanti's banter with Dhanno, the mare, to Jai and Veeru's legendary ‘dosti' and villain Gabbar Singh's inimitable dialogues, Minerva saw every tiny bit of the epic become part of people's ...

Every sailor loves a bit of breeze, but some bit off more than they could chew on Day 1 of the 2025 Nautilus Marine Insurance Sydney Short Ocean Racing Championship (SSORC) and the Seven Islands Race, ...

(RTTNews) - Minerva Neurosciences, Inc. (NERV) surged 339.33% to trade at $11.73, up $9.06, after announcing a $200 million financing deal with institutional investors to advance its schizophrenia ...

Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia. What Happened: ...

Minerva Neurosciences (NASDAQ:NERV) shares rose as much as 160% premarket on Tuesday after announcing financing of as much as $200 million and plans for NDA resubmission of its Schizophrenia drug. The ...

Investing.com -- Minerva Neurosciences (NASDAQ:NERV) stock soared 130% after the company announced it has secured up to $200 million in financing to advance its schizophrenia treatment candidate ...

Shares of Minerva Neurosciences surged more than fourfold after the company said it has secured up to $200 million in financing to advance an investigational schizophrenia treatment through a phase 3 ...